SAN DIEGO, CA, Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million Series B financing.
Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million Series B financing. The round was led by Digitalis Ventures, with continued support from BOLD Capital and Hill Creek Partners, and new participation from NovaQuest Capital Management.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
